T2 Biosystems, Inc. (TTOO)

Market Cap	8.94M
Revenue (ttm)	7.68M
Net Income (ttm)	-42.95M
Shares Out	21.04M
EPS (ttm)	-4.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,394,021
Open	0.450
Previous Close	0.425
Day's Range	0.400 - 0.459
52-Week Range	0.310 - 6.950
Beta	0.35
Analysts	Hold
Price Target	5.00 (+1,076.47%)
Earnings Date	Feb 13, 2025

About TTOO

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnosti...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 7, 2014
• Employees: 113
• Stock Exchange: NASDAQ
• Ticker Symbol: TTOO
• Website: https://www.t2biosystems.com

Financial Performance

In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.

Analyst Forecast

According to one analyst, the rating for TTOO stock is "Hold" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(1,076.47% upside)

Analyst Consensus: Hold